Alpelisib, a PI3K inhibitor, has been recently approved by the FDA for advanced or metastatic HER2-negative, hormone receptor positive with PIK3CA-mutation, that exhibits progression to endocrine therapy in breast cancer. Here, PIK3CA is linked to breast cancer.